WO2005089742A8 - 頻尿または尿失禁の予防または治療用医薬 - Google Patents

頻尿または尿失禁の予防または治療用医薬

Info

Publication number
WO2005089742A8
WO2005089742A8 PCT/JP2005/004825 JP2005004825W WO2005089742A8 WO 2005089742 A8 WO2005089742 A8 WO 2005089742A8 JP 2005004825 W JP2005004825 W JP 2005004825W WO 2005089742 A8 WO2005089742 A8 WO 2005089742A8
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
urinary incontinence
frequent urination
prevention
treatment
Prior art date
Application number
PCT/JP2005/004825
Other languages
English (en)
French (fr)
Other versions
WO2005089742A1 (ja
Inventor
Yoshinobu Yamazaki
Masami Kojima
Original Assignee
Kissei Pharmaceutical
Yoshinobu Yamazaki
Masami Kojima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical, Yoshinobu Yamazaki, Masami Kojima filed Critical Kissei Pharmaceutical
Priority to US10/599,203 priority Critical patent/US20080242674A1/en
Priority to PL05721012T priority patent/PL1728508T3/pl
Priority to DK05721012.2T priority patent/DK1728508T3/da
Priority to JP2006511224A priority patent/JP4808613B2/ja
Priority to CA002559646A priority patent/CA2559646A1/en
Priority to SI200530851T priority patent/SI1728508T1/sl
Priority to DE602005016534T priority patent/DE602005016534D1/de
Priority to EP05721012A priority patent/EP1728508B1/en
Priority to AT05721012T priority patent/ATE442137T1/de
Publication of WO2005089742A1 publication Critical patent/WO2005089742A1/ja
Publication of WO2005089742A8 publication Critical patent/WO2005089742A8/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2005/004825 2004-03-24 2005-03-17 頻尿または尿失禁の予防または治療用医薬 WO2005089742A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/599,203 US20080242674A1 (en) 2004-03-24 2005-03-17 Medicine For Prevention or Treatment of Frequent Urination or Urinary Incontinence
PL05721012T PL1728508T3 (pl) 2004-03-24 2005-03-17 Lek użyteczny do zapobiegania lub leczenia częstomoczu lub nietrzymania moczu
DK05721012.2T DK1728508T3 (da) 2004-03-24 2005-03-17 Farmaceutisk produkt til forebyggelse eller behandling af hyppig vandladning eller inkontinens
JP2006511224A JP4808613B2 (ja) 2004-03-24 2005-03-17 頻尿または尿失禁の予防または治療用医薬
CA002559646A CA2559646A1 (en) 2004-03-24 2005-03-17 Medicine for prevention or treatment of frequent urination or urinary incontinence
SI200530851T SI1728508T1 (sl) 2004-03-24 2005-03-17 Zdravilo za preprečevanje ali zdravljenje pogostega uriniranja ali urinske inkontinence
DE602005016534T DE602005016534D1 (de) 2004-03-24 2005-03-17 Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz
EP05721012A EP1728508B1 (en) 2004-03-24 2005-03-17 Medicine for prevention or treatment of frequent urination or urinary incontinence
AT05721012T ATE442137T1 (de) 2004-03-24 2005-03-17 Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2004/004000 WO2005092321A1 (ja) 2004-03-24 2004-03-24 頻尿または尿失禁の予防または治療用医薬組成物
JPPCT/JP2004/004000 2004-03-24

Publications (2)

Publication Number Publication Date
WO2005089742A1 WO2005089742A1 (ja) 2005-09-29
WO2005089742A8 true WO2005089742A8 (ja) 2005-11-03

Family

ID=34993428

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2004/004000 WO2005092321A1 (ja) 2004-03-24 2004-03-24 頻尿または尿失禁の予防または治療用医薬組成物
PCT/JP2005/004825 WO2005089742A1 (ja) 2004-03-24 2005-03-17 頻尿または尿失禁の予防または治療用医薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004000 WO2005092321A1 (ja) 2004-03-24 2004-03-24 頻尿または尿失禁の予防または治療用医薬組成物

Country Status (12)

Country Link
US (1) US20080242674A1 (ja)
EP (1) EP1728508B1 (ja)
AT (1) ATE442137T1 (ja)
CA (1) CA2559646A1 (ja)
CY (1) CY1109546T1 (ja)
DE (1) DE602005016534D1 (ja)
DK (1) DK1728508T3 (ja)
ES (1) ES2331369T3 (ja)
PL (1) PL1728508T3 (ja)
PT (1) PT1728508E (ja)
SI (1) SI1728508T1 (ja)
WO (2) WO2005092321A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
WO2008106125A2 (en) 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
EP2192903A4 (en) * 2007-10-02 2010-09-29 Dong A Pharm Co Ltd COMPOSITION AND METHOD OF TREATMENT OR METHOD PREVENTING SYMPTOMS BENIGNER PROSTATE HYPERPLASIA AND LOWER HARN
JP5553767B2 (ja) * 2008-11-07 2014-07-16 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
JP5426801B2 (ja) * 2011-08-25 2014-02-26 キッセイ薬品工業株式会社 低活動膀胱の予防または治療用医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6426517A (en) * 1987-07-21 1989-01-27 Sankyo Co Remedy for dysuria
SE504276C2 (sv) * 1993-12-30 1996-12-23 Siko Medical Ab Ventil avsedd att placeras i urinröret
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6410554B1 (en) * 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
IL157734A0 (en) * 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
JP4132020B2 (ja) * 2001-03-12 2008-08-13 キッセイ薬品工業株式会社 フェノキシ酢酸誘導体の製造中間体およびその使用方法
JP2003055261A (ja) * 2001-08-08 2003-02-26 Pfizer Prod Inc 製剤組合せ
CA2458544C (en) * 2001-09-13 2010-08-17 Kissei Pharmaceutical Co., Ltd. Crystals of hydroxynorephedrine derivative
AU2004285289A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
JP5004215B2 (ja) * 2004-03-05 2012-08-22 キッセイ薬品工業株式会社 神経障害に伴う過活動膀胱の予防または治療用医薬組成物

Also Published As

Publication number Publication date
US20080242674A1 (en) 2008-10-02
EP1728508A4 (en) 2008-02-13
ES2331369T3 (es) 2009-12-30
DK1728508T3 (da) 2010-01-25
EP1728508B1 (en) 2009-09-09
DE602005016534D1 (de) 2009-10-22
ATE442137T1 (de) 2009-09-15
WO2005092321A1 (ja) 2005-10-06
PL1728508T3 (pl) 2010-02-26
EP1728508A1 (en) 2006-12-06
SI1728508T1 (sl) 2010-01-29
CY1109546T1 (el) 2014-08-13
CA2559646A1 (en) 2005-09-29
PT1728508E (pt) 2009-10-20
WO2005089742A1 (ja) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2005089742A8 (ja) 頻尿または尿失禁の予防または治療用医薬
WO2008073785A3 (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2009063202A3 (en) Use of crth2 antagonist compounds
RU2007132725A (ru) Применение неопиатного анальгетика флупиртина для лечения гиперактивности мочевого пузыря и родственных заболеваний, в том числе неотложного недержания мочи, проблем с мочеотделением, как результата гиперплазии предстательной железы и синдрома раздраженного кишечника
WO2006113552A8 (en) Cyanoarylamines
MX2009005950A (es) Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
NZ545506A (en) Therapeutic agents useful for treating pain
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
WO2008105383A1 (ja) ピラゾール誘導体およびその医薬用途
WO2008120761A1 (ja) ヘテロアリール誘導体
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009057685A1 (ja) 過活動膀胱治療用医薬組成物
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
EP1491187A4 (en) PREVENTIVE OR THERAPEUTIC AGENT FOR RENAL DISEASES
WO2007117981A3 (en) Selective hydroxamate based mmp inhibitors
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
WO2009004914A1 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
HK1101065A1 (ja)
WO2007146224A3 (en) Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2006026273A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT IN JAPANESE REPLACED BY CORRECT ABSTRACT

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006511224

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2559646

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005721012

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10599203

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005721012

Country of ref document: EP